EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

Non-Small Cell Lung Cancer Clinical Trial

— EXLIBRIS  

Official title:

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06448572
• Other study ID #: 2022-0641
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: September 1, 2024
• Est. completion date: December 1, 2028

Study information

• Verified date: June 2024
• Source: University Hospital, Lille
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

As treatment options are limited following progression on anti PD-(L)1 and platinum-based chemotherapy, we propose this trial for patients who have failed to respond or have shown intolerance to standard therapies or for whom no appropriate therapies are known to provide clinical benefit. Considering the strong therapeutic rationale of an association between antineoplastic immunotherapy and EXL01 (single-strain of F. prausnitzii, a bacteria which is a dominant member of the healthy gut microbiota), we propose to assess this combination for NSCLC treatment. This is a pilot, Phase I/II, one-arm, monocentric study evaluating the combination of EXL01 with nivolumab treatment for Non-Small Cell Lung Cancer patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 21
• Est. completion date: December 1, 2028
• Est. primary completion date: December 1, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients (male or female) =18 years old.

2. ECOG Performance status (PS) 0-1 (WHO).

3. Histologically or cytologically documented inoperable advanced/metastatic NSCLC. (inoperable stage III not amenable to radiation therapy or surgery, stage IV)

4. No alterations of key driver oncogenes including EGFR (mutations), ALK (fusions), ROS1 (fusions), MET (METex14 mutations), HER2 (exon 20 insertions), RET (fusions), or BRAF (V600E mutations). KRAS mutations are allowed.

5. Must have previously received anti-PD(L)1 agent and platinum-based chemotherapy, either concomitantly or sequentially. Last dose to have been administered more than 15 days prior to first dose of study drug.

6. Must have progressed within 6 months after first dose of anti-PD(L)1 given either alone or in combination with platinum-based chemotherapy.

7. Must have received all validated available standard therapies.

8. Measurable disease according to iRECIST 1.1.

9. Adequate hematological, renal and liver functions within 72 hours before the first

dose of study treatment:

• Absolute Neutrophil Count = 1500/µL
• Platelets = 100 000/µL
• Hemoglobin = 9.0 g/dL
• Creatinine Clearance = 50 mL/min
• Total Bilirubin = 1.5 x ULN
• AST and ALT = 2.5 x ULN (= 5 x ULN for participants with liver metastasis)

Exclusion Criteria:

1. Small cell lung cancer or tumors with mixed histology including a SCLC component.

2. Known symptomatic CNS metastases and/or carcinomatous meningitis. Participants with asymptomatic brain metastases (ie, no neurological symptoms and no requirements for corticosteroids > 10mg/d prednisone equivalent) may participate.

3. Diagnosis of immunodeficiency of is receiving systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 14 days before initiation of the immunotherapy induction. Inhaled, nasal or topic corticosteroids are allowed.

4. Living attenuated vaccine received within the 30 previous days.

5. Has received Fecal Microbiota Transplantation within 3 months prior to Screening.

6. General serious condition such as uncontrolled congestive cardiac failure, uncontrolled cardiac arrythmia, uncontrolled ischemic cardiac disease (unstable angina or history of myocardial infarction within the previous 6 months), history or stroke within the 6 previous months.

7. History of severe immune-mediated toxicity (= grade 3) under immunotherapy treatment.

8. History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Cancer

Intervention

Drug:
• EXL01
1 capsule / day

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Lille	Exeliom Biosciences

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival rate (PFS Rate) for the assessment of efficacy, defined as the rate of alive and non-progressive subjects as per iRECIST 1.1 over the study subjects.		At 3 months from the inclusion
Secondary	Number of Grade = 3 treatment-related AEs, using CTCAE		First 6 weeks of treatment
Secondary	Progression Free Survival, defined as the time from inclusion to the first documented disease progression or death due to any cause, whichever occurs first.		First 6 weeks of treatment
Secondary	ORR (Overall Response Rate) as per iRECIST1.1 for the assessment of efficacy, defined as the rate of confirmed Complete Response (CR) or Partial Response (PR) over the study subjects efficacy responses.		First 6 weeks of treatment
Secondary	Overall Survival, defined as the time from inclusion to the date of death due to any cause		First 6 weeks of treatment
Secondary	Disease Control Rate, defined as the rate of confirmed Complete Response (CR), or Partial Response (PR), or Stable Disease (SD) over the study subjects efficacy responses		First 6 weeks of treatment